Juno Therapeutics Shares Rebound From Lows But Still Down 6.5% For Session; Traders Recently Circulating Chatter Celgene Has No Interest In Co.; BZ NOTE: Chatter Related To Juno, Celgene Were Heard Several Times Over The Course Of '17
Paul Quintaro